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current health state was 0.74 (possible utility scores range
from 0 to 1). Current health ratings were signiﬁcantly cor-
related with inattentive, hyperactive, and overall symp-
toms of ADHD (0.37, 0.36, and 0.40; p < 0.05). SG
ratings of hypothetical health states ranged from 0.48
(severe untreated ADHD) to 0.88 (effective, tolerable ato-
moxetine treatment). Comparisons between health states
found expected differences between untreated mild, mod-
erate, and severe ADHD health states. When both treat-
ments were effective and tolerable, parents preferred
atomoxetine to stimulants (p < 0.03). CONCLUSIONS:
SG ratings of current health demonstrated construct
validity through signiﬁcant correlations with ADHD
symptoms. Statistical comparisons revealed signiﬁcant
differences between treatment-related health states. In
sum, parent SG interviews appear to be a valid method
for obtaining utility scores that can be used in cost-
effectiveness models of ADHD treatment.
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OBJECTIVES: Major depressive disorder (MDD) is asso-
ciated with impaired patient functioning and signiﬁcant
reductions in health-related quality of life (HRQL). Anti-
depressant treatments aim to increase patient rates of sus-
tained remission as early as possible, and our objective
was to study the impact of early sustained remission on
patient’s HRQL. METHODS: A total of 250 patients
with a DSM-IV diagnosis of MDD under treatment with
selective serotonin reuptake inhibitors were selected for
an observational 8-week follow-up study. Patient assess-
ments included the Montgomery-Asberg Depression
Rating Scale (MADRS), the Short Form-36 Item scale (SF-
36) and the EuroQoL (EQ-5D). The MADRS was per-
formed at baseline, weeks 2, 3, 4, and 8 and HRQL scales
were performed at baseline and week 8. Remission was
deﬁned using the MADRS cut-off value of 12. Five sub-
groups were deﬁned: remitters at week 2 (G1), week 3
(G2), week 4 (G3), week 8 (G4) and non-remitters at
week 8 (G5). Multivariate analyses of variance were used
to assess the differences of HRQL among these groups
after adjustment on centre and baseline MADRS scores.
RESULTS: The distribution of patients across groups was
6.7% (G1), 16.8% (G2), 12.4% (G3), 21.2% (G4) and
42.9% (G5). After adjustment, HRQL assessed by EQ-
5D was signiﬁcantly higher for remitters (G1: 0.81 ± 0.08;
G2: 0.79 ± 0.16; G3: 0.77 ± 0.20; G4: 0.71 ± 0.21; G5:
0.57 ± 0.28; p < 0.001). The same results were found with
the SF-36 Physical and Mental Composite Summary
scores (p < 0.001 for both) as well as SF-36 subscales 
(p < 0.001). Early sustained remitters reported higher EQ-
5D scores (G1 and G2 versus G3 and G4, p < 0.05).
CONCLUSION: The results of this observational study
clearly show the major impact of sustained remission on
HRQL in MDD. Time to sustained remission may have
a major impact on patient’s HRQL and might become a
pre-requisite for approval and reimbursement of new
antidepressant compounds.
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OBJECTIVES: The published literature concerning
Health-Related Quality of Life (HRQL) in Major Depres-
sive Disorder (MDD) does not provide clear guidelines
between the use of generic and speciﬁc HRQL measures
from an evaluative perspective, though disease-speciﬁc
instruments are thought to be more sensitive to change.
Using data from two studies in which both generic 
and speciﬁc HRQL measurements were available, we
attempted to compare the relevance of both types of
instruments according to their sensibility to change and
the information provided. METHODS: Two randomised,
double blind, active-controlled, 8-week studies of esci-
talopram were used. In the ﬁrst study, 165 patients com-
pleted the generic SF-36 and the disease-speciﬁc Quality
of Life Depression Scale (QLDS). In the second study, 146
patients reported HRQL using the EuroQoL and QLDS
scales. Clinical efﬁcacy was assessed in both studies 
using the Montgomery-Asberg Depression Rating Scale
(MADRS). Results were adjusted for sustained remission
(from the assessment at which remission was achieved
until study termination) using the MADRS lesser than 
or equal to 12 criterion. RESULTS: In the ﬁrst study,
patients treated with Escitalopram showed signiﬁcant
improvement on all SF-36 subscales. Mean SF-36 changes
from baseline were signiﬁcantly different from 0. Esti-
mated effect sizes ranged from 0.52 (bodily pain) to 1.75
(mental health), indicating a moderate to large improve-
ment in HRQL. Using the same methodology, QLDS esti-
mated effect size was 1.04, indicating a large HRQL
improvement. In the study in which both EuroQoL and
QLDS scales were completed, signiﬁcant results were
obtained for both instruments. Estimated effect sizes were
0.79 and 0.98 for EuroQoL and QLDS respectively.
CONCLUSION: The results of these two studies clearly
demonstrated the ability of both instruments to be 
sensitive to changes. Yet, with similar effect sizes, the
generic SF-36 provided more information relative to the
different sub-scales affected than the disease speciﬁc
QLDS.
